{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T18:07:12Z","timestamp":1776276432943,"version":"3.50.1"},"reference-count":43,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2027,3,26]],"date-time":"2027-03-26T00:00:00Z","timestamp":1806019200000},"content-version":"am","delay-in-days":298,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015691","name":"National Institute of Allergy and Infectious Diseases Division of Microbiology and Infectious Diseases","doi-asserted-by":"publisher","award":["AI154656"],"award-info":[{"award-number":["AI154656"]}],"id":[{"id":"10.13039\/100015691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Virology"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.virol.2026.110884","type":"journal-article","created":{"date-parts":[[2026,3,21]],"date-time":"2026-03-21T16:25:15Z","timestamp":1774110315000},"page":"110884","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Low-dose multivalent COVID-19 mRNA vaccines enhance broadly cross-reactive antibodies and protective immune responses of co-administered protein-based vaccines"],"prefix":"10.1016","volume":"619","author":[{"given":"Rong","family":"Liu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lila D.","family":"Patterson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mahmuda","family":"Yeasmin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ki-Hye","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bo Ryoung","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noopur","family":"Bhatnagar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jannatul Ruhan","family":"Raha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Phillip","family":"Grovenstein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Surya Sekhar","family":"Pal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chau Thuy Tien","family":"Le","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chong Hyun","family":"Shin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lanying","family":"Du","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0970-4875","authenticated-orcid":false,"given":"Mukesh","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6198-331X","authenticated-orcid":false,"given":"Sang-Moo","family":"Kang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.virol.2026.110884_bib1","doi-asserted-by":"crossref","first-page":"2877","DOI":"10.1016\/j.immuni.2021.11.001","article-title":"Lipid nanoparticles enhance the efficacy of mRNA and protein subunit vaccines by inducing robust T follicular helper cell and humoral responses","volume":"54","author":"Alameh","year":"2021","journal-title":"Immunity"},{"key":"10.1016\/j.virol.2026.110884_bib2","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1016\/j.cmi.2023.03.007","article-title":"Immunogenicity of omicron BA.1-adapted BNT162b2 vaccines: randomized trial, 3-month follow-up","volume":"29","author":"Barda","year":"2023","journal-title":"Clin. Microbiol. Infect."},{"key":"10.1016\/j.virol.2026.110884_bib3","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.40364","article-title":"Analysis of COVID-19 vaccine type and adverse effects following vaccination","volume":"4","author":"Beatty","year":"2021","journal-title":"JAMA Netw. Open"},{"key":"10.1016\/j.virol.2026.110884_bib4","article-title":"SARS-CoV-2 mRNA vaccines: immunological mechanism and beyond","volume":"9","author":"Bettini","year":"2021","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.virol.2026.110884_bib5","article-title":"Co-Administration of BNT162b2 COVID-19 and influenza vaccines in adults: a global systematic review","volume":"13","author":"Boikos","year":"2025","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.virol.2026.110884_bib6","doi-asserted-by":"crossref","first-page":"6585","DOI":"10.1016\/j.vaccine.2006.05.040","article-title":"The humoral immune response and protective efficacy of vaccination with inactivated split and whole influenza virus vaccines in BALB\/c mice","volume":"24","author":"Cox","year":"2006","journal-title":"Vaccine"},{"key":"10.1016\/j.virol.2026.110884_bib7","article-title":"The equal neutralizing effectiveness of BNT162b2, ChAdOx1 nCoV-19, and sputnik V vaccines in the Palestinian population","volume":"12","author":"Damour","year":"2024","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.virol.2026.110884_bib8","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/S1473-3099(24)00101-4","article-title":"Interim safety and immunogenicity of COVID-19 omicron BA.1 variant-containing vaccine in children in the USA: an open-label non-randomised phase 3 trial","volume":"24","author":"Dixit","year":"2024","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.virol.2026.110884_bib9","article-title":"Immunogenicity and protectivity of sputnik V vaccine in hACE2-Transgenic mice against homologous and heterologous SARS-CoV-2 lineages including far-distanced omicron BA.5","volume":"12","author":"Dolzhikova","year":"2024","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.virol.2026.110884_bib10","doi-asserted-by":"crossref","DOI":"10.1002\/hsr2.70166","article-title":"Current updates on variants of SARS-CoV- 2: systematic review","volume":"7","author":"Erkihun","year":"2024","journal-title":"Health Sci. Rep."},{"key":"10.1016\/j.virol.2026.110884_bib11","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1016\/j.ymthe.2020.04.018","article-title":"A multi-targeting, nucleoside-modified mRNA influenza virus vaccine provides broad protection in mice","volume":"28","author":"Freyn","year":"2020","journal-title":"Mol. Ther."},{"key":"10.1016\/j.virol.2026.110884_bib12","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1093\/jimmun\/vkae013","article-title":"Influenza 5xM2e mRNA lipid nanoparticle vaccine confers broad immunity and significantly enhances the efficacy of inactivated split vaccination when coadministered","volume":"214","author":"Grovenstein","year":"2025","journal-title":"J. Immunol."},{"key":"10.1016\/j.virol.2026.110884_bib13","doi-asserted-by":"crossref","DOI":"10.1128\/spectrum.01315-22","article-title":"Correlation of SARS-CoV-2 viral neutralizing antibody titers with anti-spike antibodies and ACE-2 inhibition among vaccinated individuals","volume":"10","author":"Grunau","year":"2022","journal-title":"Microbiol. Spectr."},{"key":"10.1016\/j.virol.2026.110884_bib14","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1111\/j.1365-3083.2005.01633.x","article-title":"Whole influenza virus vaccine is more immunogenic than split influenza virus vaccine and induces primarily an IgG2a response in BALB\/c mice","volume":"62","author":"Hovden","year":"2005","journal-title":"Scand. J. Immunol."},{"key":"10.1016\/j.virol.2026.110884_bib15","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1407149","article-title":"Research progress of spike protein mutation of SARS-CoV-2 mutant strain and antibody development","volume":"15","author":"Huan","year":"2024","journal-title":"Front. Immunol."},{"key":"10.1016\/j.virol.2026.110884_bib16","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.virol.2016.04.014","article-title":"Combined virus-like particle and fusion protein-encoding DNA vaccination of cotton rats induces protection against respiratory syncytial virus without causing vaccine-enhanced disease","volume":"494","author":"Hwang","year":"2016","journal-title":"Virology"},{"key":"10.1016\/j.virol.2026.110884_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.vaccine.2025.126754","article-title":"Safety comparison between Pfizer BNT162b2, moderna mRNA-1273, and AstraZeneca AZD1222 in a Nationwide prospective cohort survey at the beginning of the severe acute respiratory syndrome coronavirus 2 vaccination in Japan","volume":"49","author":"Ito","year":"2025","journal-title":"Vaccine"},{"key":"10.1016\/j.virol.2026.110884_bib18","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/s41541-021-00324-5","article-title":"Immunogenicity and efficacy of mRNA COVID-19 vaccine MRT5500 in preclinical animal models","volume":"6","author":"Kalnin","year":"2021","journal-title":"npj Vaccines"},{"key":"10.1016\/j.virol.2026.110884_bib19","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1038\/mt.2008.200","article-title":"Incorporation of pseudouridine into mRNA yields superior nonimmunogenic vector with increased translational capacity and biological stability","volume":"16","author":"Kariko","year":"2008","journal-title":"Mol. Ther."},{"key":"10.1016\/j.virol.2026.110884_bib20","article-title":"Responses to common misconceptions relating to COVID-19 variant-adapted mRNA vaccines","volume":"12","author":"Kassianos","year":"2024","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.virol.2026.110884_bib21","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1038\/s41591-021-01377-8","article-title":"Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection","volume":"27","author":"Khoury","year":"2021","journal-title":"Nat. Med."},{"key":"10.1016\/j.virol.2026.110884_bib22","article-title":"Immunogenicity and neutralizing activity comparison of SARS-CoV-2 spike full-length and subunit domain proteins in young adult and old-aged mice","volume":"9","author":"Kim","year":"2021","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.virol.2026.110884_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.virol.2025.110674","article-title":"Interferon-gamma receptor signaling is critical for balanced immune activation and protection against influenza after vaccination","volume":"612","author":"Kim","year":"2025","journal-title":"Virology"},{"key":"10.1016\/j.virol.2026.110884_bib24","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1038\/mt.2012.246","article-title":"Virus-like particles containing multiple M2 extracellular domains confer improved cross-protection against various subtypes of influenza virus","volume":"21","author":"Kim","year":"2013","journal-title":"Mol. Ther. : J. Amer. Soc. Gene Ther."},{"key":"10.1016\/j.virol.2026.110884_bib25","doi-asserted-by":"crossref","first-page":"6932","DOI":"10.1016\/j.vaccine.2009.08.108","article-title":"Improved influenza vaccination in the skin using vaccine coated microneedles","volume":"27","author":"Kim","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.virol.2026.110884_bib26","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.antiviral.2018.06.004","article-title":"MPL and CpG combination adjuvants promote homologous and heterosubtypic cross protection of inactivated split influenza virus vaccine","volume":"156","author":"Ko","year":"2018","journal-title":"Antivir. Res."},{"key":"10.1016\/j.virol.2026.110884_bib27","doi-asserted-by":"crossref","first-page":"eadu8067","DOI":"10.1126\/scitranslmed.adu8067","article-title":"The XBB.1.5 COVID-19 vaccine elicits a durable antibody response to ancestral and XBB.1.5 SARS-CoV-2 spike proteins","volume":"17","author":"Kumar","year":"2025","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.virol.2026.110884_bib28","doi-asserted-by":"crossref","DOI":"10.1128\/jvi.02294-24","article-title":"Dual roles of influenza B virus neuraminidase mRNA vaccine in enhancing cross-lineage protection by supplementing inactivated split vaccination","volume":"99","author":"Le","year":"2025","journal-title":"J. Virol."},{"key":"10.1016\/j.virol.2026.110884_bib29","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1038\/s41590-022-01163-9","article-title":"Mechanisms of innate and adaptive immunity to the Pfizer-BioNTech BNT162b2 vaccine","volume":"23","author":"Li","year":"2022","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.virol.2026.110884_bib30","article-title":"Multivalent and sequential heterologous spike protein vaccinations effectively induce protective humoral immunity against SARS-CoV-2 variants","volume":"12","author":"Liu","year":"2024","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.virol.2026.110884_bib31","doi-asserted-by":"crossref","first-page":"7021","DOI":"10.1016\/j.vaccine.2021.10.054","article-title":"COVID-19 vaccination significantly reduces morbidity and absenteeism among healthcare personnel: a prospective multicenter study","volume":"39","author":"Maltezou","year":"2021","journal-title":"Vaccine"},{"key":"10.1016\/j.virol.2026.110884_bib32","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.701501","article-title":"SARS-CoV-2 vaccines based on the spike glycoprotein and implications of new viral variants","volume":"12","author":"Martinez-Flores","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.virol.2026.110884_bib33","doi-asserted-by":"crossref","first-page":"24075","DOI":"10.1073\/pnas.1908052116","article-title":"mRNA structure regulates protein expression through changes in functional half-life","volume":"116","author":"Mauger","year":"2019","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.virol.2026.110884_bib34","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1016\/j.vaccine.2022.12.069","article-title":"Safety of co-administration of mRNA COVID-19 and seasonal inactivated influenza vaccines in the vaccine adverse event reporting system (VAERS) during July 1, 2021-June 30, 2022","volume":"41","author":"Moro","year":"2023","journal-title":"Vaccine"},{"key":"10.1016\/j.virol.2026.110884_bib35","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2021.103479","article-title":"The mRNA-LNP platform's lipid nanoparticle component used in preclinical vaccine studies is highly inflammatory","volume":"24","author":"Ndeupen","year":"2021","journal-title":"iScience"},{"key":"10.1016\/j.virol.2026.110884_bib36","doi-asserted-by":"crossref","DOI":"10.3390\/v16010064","article-title":"Generation and characterization of a multi-functional panel of monoclonal antibodies for SARS-CoV-2 research and treatment","volume":"16","author":"Patterson","year":"2023","journal-title":"Viruses"},{"key":"10.1016\/j.virol.2026.110884_bib37","doi-asserted-by":"crossref","DOI":"10.3390\/microorganisms11020368","article-title":"Severe acute respiratory syndrome coronavirus 2 receptor (human angiotensin-converting enzyme 2) binding inhibition assay: a rapid, high-throughput assay useful for vaccine immunogenicity evaluation","volume":"11","author":"Plested","year":"2023","journal-title":"Microorganisms"},{"key":"10.1016\/j.virol.2026.110884_bib38","doi-asserted-by":"crossref","first-page":"ofac314","DOI":"10.1093\/ofid\/ofac314","article-title":"An analysis of SARS-CoV-2 vaccine reactogenicity: variation by type, dose, and history, severity, and recency of prior SARS-CoV-2 infection","volume":"9","author":"Scher","year":"2022","journal-title":"Open Forum Infect. Dis."},{"key":"10.1016\/j.virol.2026.110884_bib39","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-024-54384-x","article-title":"A potent broad-spectrum neutralizing antibody targeting a conserved region of the prefusion RSV F protein","volume":"15","author":"Sun","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.virol.2026.110884_bib40","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1038\/s41422-020-0387-5","article-title":"A novel receptor-binding domain (RBD)-based mRNA vaccine against SARS-CoV-2","volume":"30","author":"Tai","year":"2020","journal-title":"Cell Res."},{"key":"10.1016\/j.virol.2026.110884_bib41","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1016\/j.immuni.2022.10.014","article-title":"Innate immune mechanisms of mRNA vaccines","volume":"55","author":"Verbeke","year":"2022","journal-title":"Immunity"},{"key":"10.1016\/j.virol.2026.110884_bib42","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1021\/acscentsci.1c00080","article-title":"Native-like SARS-CoV-2 spike glycoprotein expressed by ChAdOx1 nCoV-19\/AZD1222 vaccine","volume":"7","author":"Watanabe","year":"2021","journal-title":"ACS Cent. Sci."},{"key":"10.1016\/j.virol.2026.110884_bib43","doi-asserted-by":"crossref","DOI":"10.1002\/iid3.807","article-title":"Adverse events following COVID-19 mRNA vaccines: a systematic review of cardiovascular complication, thrombosis, and thrombocytopenia","volume":"11","author":"Yasmin","year":"2023","journal-title":"Immun. Inflamm. Dis."}],"container-title":["Virology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0042682226000991?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0042682226000991?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T17:17:59Z","timestamp":1776273479000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0042682226000991"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":43,"alternative-id":["S0042682226000991"],"URL":"https:\/\/doi.org\/10.1016\/j.virol.2026.110884","relation":{},"ISSN":["0042-6822"],"issn-type":[{"value":"0042-6822","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Low-dose multivalent COVID-19 mRNA vaccines enhance broadly cross-reactive antibodies and protective immune responses of co-administered protein-based vaccines","name":"articletitle","label":"Article Title"},{"value":"Virology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.virol.2026.110884","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"110884"}}